Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This cluster randomized clinical trial at 18 nurse-led rural health centers in Lesotho will test an automated differentiated service delivery model using viral load results, other clinical characteristics and participants' preference to automatically triage participants into groups requiring different levels of attention and care.
To sustainably provide good quality care to increasing numbers of people living with HIV (PLHIV) receiving antiretroviral therapy (ART), care delivery has to shift from a "one-size-fits-all" approach to differentiated care models. Such models should reallocate resources from patients who are doing well to patient groups who may need more attention, such as those with treatment failure or medical and psycho-social problems. Ideally, such a reallocation allows health systems and patients to save resources while improving quality of care.
One proposed approach to differentiate care and intensity of monitoring is viral load-driven differentiated service delivery. Reducing the intensity of monitoring in patients with suppressed viral load (VL) and no other clinical problems would substantially reduce the workload at health care facilities and save time and transport cost for patients, thus potentially improve long-term engagement in care. Time and resources saved in patients with suppressed VL and no other clinical problems would allow focusing on those participants with elevated viral load and/or other clinical problems (like tuberculosis, which is the most common cause of mortality among PLHIV in sub-Saharan Africa). This may potentially improve PLHIVs' clinical outcome through intensified adherence support, clinical follow-up and timely switches to second-line ART. In many settings in sub-Saharan Africa, however, the potential of VL monitoring to differentiate care is not exploited and thus constitutes a missed opportunity. In Lesotho it was shown that the majority of unsuppressed VLs are not acted upon in a timely manner, be it due to providers and patients not being aware of the results or health care providers not being proficient in the management of treatment failure.
The concept of the proposed automated differentiated service delivery model (aDSDM) is to use VL results, other clinical characteristics (TB screening results and CD4 cell counts) and participants' preference to automatically triage participants into groups requiring different levels of attention and care. Innovatively, triaging of participants will be done automatically capitalising on an existing VL database platform. The implemented aDSDM will differentiate care according to three elements:
To ensure effective flow of information, VL results and other relevant information is sent directly to participants' phones, whereas health care providers receive results directly on their study tablet together with the recommended action. Further features of the platform are preference-based tailored adherence reminders and automated calls to participants for symptomatic tuberculosis screening. The proposed aDSDM is designed for being scaled up at national and regional level as it mainly builds on automated triage and communication with participants and health care workers, thus not requiring additional human resources.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention | Experimental | Clusters in the intervention arm receive the VITAL intervention (see intervention) |
|
| Control | No Intervention | Clusters in the control arm continue standard of care. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| VITAL model | Behavioral | The concept of the VITAL, an automated differentiated service delivery model (aDSDM), is to use viral load results, other clinical characteristics (TB screening results and CD4 cell counts, comorbidities) and participants' preference to automatically triage participants into groups requiring different levels of attention and care. Innovatively, triaging of participants will be done automatically making use of a dedicated mobile App and a viral load database platform. To ensure effective flow of information and empowerment of patients, viral load results and other relevant information is sent directly to participants' phones, whereas health care providers receive results directly on their study tablet together with the recommended action. Further features of the platform are preference-based tailored adherence reminders and automated calls to participants for symptomatic tuberculosis screening. |
| Measure | Description | Time Frame |
|---|---|---|
| Engagement in care with documented viral suppression | Proportion of participants engaged in care (defined as documented visit attendance) with documented viral suppression (<50 copies/mL) 24 months (16-28 months) after enrollment | 16-28 months after enrollment |
| Measure | Description | Time Frame |
|---|---|---|
| Viral re-suppression | Proportion of participants with viral re-suppression (<50 copies/mL) 24 months (16-28 months) after enrollment among all participants with an unsuppressed VL (≥ 50 copies/mL) during the first 12 months of follow-up | 16-28 months after enrollment |
| Sustained viral suppression |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of participants requesting a VL result notification through SMS | in intervention clusters | at 24 months after enrollment |
| Proportion of SMS delivered successfully | in intervention clusters |
Inclusion criteria:
Exclusion criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Niklaus Labhardt, Prof | University Hospital, Basel, Switzerland | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Boiketsiso Health Center | Butha-Buthe | Lesotho | ||||
| Linakeng Health Center |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 35511950 | Background | Tschumi N, Lerotholi M, Kopo M, Kao M, Lukau B, Nsakala B, Chejane N, Motaboli L, Lee T, Barnabas R, Shapiro AE, van Heerden A, Lejone TI, Amstutz A, Brown JA, Heitner J, Belus JM, Chammartin F, Labhardt ND. Assessment of a viral load result-triggered automated differentiated service delivery model for people taking ART in Lesotho (the VITAL study): Study protocol of a cluster-randomized trial. PLoS One. 2022 May 5;17(5):e0268100. doi: 10.1371/journal.pone.0268100. eCollection 2022. | |
| 42005925 |
Not provided
Not provided
A subset of the key pseudo-anonymised individual participant data collected during the study, along with a data dictionary, will be made available upon request to the Division of Clinical Epidemiology at the University Hospital Basel.
upon publication of the trial results
upon request
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| SAP | No | Yes | No | Statistical Analysis Plan | Jul 28, 2025 | Jul 29, 2025 | SAP_001.pdf |
Not provided
| ID | Term |
|---|---|
| D015658 | HIV Infections |
| ID | Term |
|---|---|
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
| D015229 | Sexually Transmitted Diseases, Viral |
Not provided
Not provided
cluster-randomized
Not provided
Not provided
Not provided
Not provided
|
|
Proportion of participants with sustained viral suppression (defined as >1 VL <50 copies/mL) during 24 months (16-28 months) follow-up |
| 16-28 months after enrollment |
| Mortality rate | All-cause mortality | at 12 and 24 months after enrollment |
| Tuberculosis | Proportion of participants with confirmed tuberculosis diagnosis | at 12 and 24 months after enrollment |
| Disengagement from care | Proportion of participants disengaged from care (defined as no documented visit attendance) at 12 months (8-16 months) and 24 months (16-28 months) after enrollment | at 12 and 24 months after enrollment |
| Time to follow-up | Time to follow-up viral load in case of an unsuppressed VL (≥50 copies/mL) | at 24 months after enrollment |
| Time to ART regimen adaption | Time to ART regimen adaption in case of virologic failure | at 24 months after enrollment |
| Rate of clinic visits | Number of clinic visits throughout the study period | at 24 months after enrollment |
| Proportion of participants with ART regimen modification | 12. Proportion of participants with ART regimen modification due to virologic failure at 12 and 24 months among participants with virologic failure | at 12 and 24 months after enrollment |
| Proportion of participants receiving a course of TPT | Proportion of participants having received a course of TPT throughout the study period. | at 24 months after enrollment |
| at 24 months after enrollment |
| Proportion of participants using the call-back option through District ART Nurse | in intervention clusters | at 24 months after enrollment |
| Butha-Buthe |
| Lesotho |
| Makhunoane Health Center | Butha-Buthe | Lesotho |
| Motete Health Center | Butha-Buthe | Lesotho |
| Muela Health Center | Butha-Buthe | Lesotho |
| Ngoajane Health Center | Butha-Buthe | Lesotho |
| Rampai Health Center | Butha-Buthe | Lesotho |
| St Paul Health Center | Butha-Buthe | Lesotho |
| St. Peters Health Center | Butha-Buthe | Lesotho |
| Tsime Health Center | Butha-Buthe | Lesotho |
| Libibing | Mokhotlong | Lesotho |
| Linakaneng health center | Mokhotlong | Lesotho |
| Malefiloane health center | Mokhotlong | Lesotho |
| Mapholaneng | Mokhotlong | Lesotho |
| Moeketsane | Mokhotlong | Lesotho |
| Molikaliko health center | Mokhotlong | Lesotho |
| St. James | Mokhotlong | Lesotho |
| St. Martins | Mokhotlong | Lesotho |
| Derived |
| Tschumi N, Lerotholi M, Kopo M, Kao M, Motaboli L, Mokebe M, Chejane N, Chakela M, Nsakala BL, Lukau B, van Heerden A, Barnabas RV, Heitner J, Shapiro AE, Urda L, Sanchez G, Lee T, Brown JA, Amstutz A, Belus JM, Chammartin F, Labhardt ND. Integrating clinical decision support and mobile health for differentiated HIV service delivery in Lesotho (VITAL): a cluster-randomised non-inferiority trial. EClinicalMedicine. 2026 Apr 2;94:103850. doi: 10.1016/j.eclinm.2026.103850. eCollection 2026 Apr. |
| 39354488 | Derived | Harder MT, Mokete M, Chammartin F, Lerotholi M, Motaboli L, Kopo M, Kao M, Mokebe M, Chejane N, Mahlatsi P, Nyakane M, Tarumbiswa T, Labhardt ND, Tschumi N, Belus JM. Cervical cancer screening delay and associated factors among women with HIV in Lesotho: a mixed-methods study. BMC Womens Health. 2024 Oct 1;24(1):543. doi: 10.1186/s12905-024-03382-8. |
| D012749 | Sexually Transmitted Diseases |
| D016180 | Lentivirus Infections |
| D012192 | Retroviridae Infections |
| D012327 | RNA Virus Infections |
| D014777 | Virus Diseases |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D007153 | Immunologic Deficiency Syndromes |
| D007154 | Immune System Diseases |